eMedicine Specialties > Ophthalmology > Intraocular Pressure

Glaucoma, Phacomorphic: Treatment & Medication

Author: Harpreet Gill, MD, Staff Physician, Henry Ford Ophthalmology
Coauthor(s): Mark S Juzych, MD, MHSA, Chief, Department of Ophthalmology, Harper Hospital; Associate Chair and Program Director, Associate Professor, Department of Ophthalmology, Kresge Eye Institute, Wayne State University School of Medicine; Anju Gupta Goyal, MD, Assistant Professor of Ophthalmology, Kresge Eye Institute, Wayne State University; Director of Resident's Clinic, Kresge Eye Institute
Contributor Information and Disclosures

Updated: Jan 7, 2008

Treatment

Medical Care

Medical treatment of phacomorphic glaucoma is aimed at rapidly reducing the IOP to prevent further damage to the optic nerve, to clear the cornea, and to prevent synechiae formation. The reduction of IOP is necessary to prepare the patient for laser iridotomy, which relieves the pupillary block that is causing the glaucoma.

  • Initial management should address the acute nature of the angle closure and include beta-blockers, alpha 2-adrenergic agonists, and carbonic anhydrase inhibitors. Miotics can worsen the secondary angle closure attack by increasing iridolenticular contact.
  • Secondary management begins with laser iridotomy to relieve the pupillary block.
    • This procedure provides an alternate route for aqueous trapped in the posterior chamber to enter the AC, allowing the iris to recede from occluding the trabecular meshwork. Both the argon laser and the Nd:YAG laser can be used.
    • Laser iridectomy sometimes relieves the acute angle-closure attack, but the AC remains shallow. These eyes are susceptible to repeated attacks of angle closure; therefore, cataract extraction should be performed if the AC does not deepen after laser iridectomy.
  • Gonioscopy is useful after an iridectomy for retrospective assessment of the angle. If the angle is markedly widened, the pupillary block was the likely main mechanism causing the elevated IOP, and laser iridectomy is sufficient in that case. If the angle does not deepen significantly, lens intumescence or forward displacement of the lens is the causative factor, and the patient needs cataract extraction. If the angle closure is not relieved by a laser iridotomy, plateau iris syndrome also is a differential diagnosis.
  • OCT may serve as an additional aid in establishing a diagnosis prelaser and postlaser.

Surgical Care

  • Laser iridotomy can temporarily stop an attack of acute pupillary block, but, in most patients with phacomorphic glaucoma, cataract extraction is needed. Laser iridotomy should be performed first as mydriasis because surgery can exacerbate the condition. An extracapsular approach typically is used for cataract extraction. A trabeculectomy often is combined with cataract extraction.
  • Surgery in the nanophthalmic eye is not the procedure of choice; laser peripheral iridectomy and iridoplasty with medical therapy are recommended. The nanophthalmic eye is small with a shallow chamber and moderate-to-high hyperopia. In these patients, cataract extraction has a high rate of exudative detachment of the choroid and ciliary body with rhegmatogenous retinal detachment.
  • On initial puncture of the capsule on an intumescent lens, an increased risk of a tear extending to the equator exists due to increased pressure forces as the liquefied cortex egresses. One method for dealing with this possibility is using a 30-gauge needle on a syringe to aspirate the liquefied cortex as the capsule is punctured. This provides for a controlled lens decompression.
  • Because of the increased risk of complications during cataract extraction, deepening of the AC with pars plana vitreous tap or small-gauge vitrectomy has been suggested.1

Medication

The goals of pharmacotherapy are to reduce morbidity and to prevent complications.

Carbonic anhydrase inhibitors

Carbonic anhydrase is an enzyme found in many tissues of the body, including the eye. Catalyzes a reversible reaction where carbon dioxide becomes hydrated and carbonic acid becomes dehydrated. By slowing the formation of bicarbonate ions with subsequent reduction in sodium and fluid transport, it may inhibit carbonic anhydrase in the ciliary processes of the eye. This effect decreases aqueous humor secretion, reducing IOP.


Acetazolamide (Diamox, Diamox Sequels)

Inhibits enzyme carbonic anhydrase, reducing the rate of aqueous humor formation, which, in turn, reduces IOP.

Adult

250-500 mg IV/IM; may repeat in 2-4 h to maximum 1 g/d

Pediatric

8-30 mg/kg/d or 300-900 mg/m2/d IV/IM divided q8h

Can decrease therapeutic levels of lithium and alter excretion of drugs (eg, amphetamines, quinidine, phenobarbital, salicylates) by alkalinizing urine

Documented hypersensitivity; hepatic disease; severe renal disease; adrenocortical insufficiency; severe pulmonary obstruction

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Patients with impaired hepatic function may go into coma; may cause substantial increase in blood glucose in some diabetic patients


Dorzolamide (Trusopt)

Used concomitantly with other topical ophthalmic drug products to lower IOP. If more than one ophthalmic drug is being used, administer the drugs at least 10 min apart. Reversibly inhibits carbonic anhydrase, reducing hydrogen ion secretion at renal tubule and increasing renal excretion of sodium, potassium bicarbonate, and water to decrease production of aqueous humor.

Adult

1 gtt in affected eye(s) tid

Pediatric

Not established

Coadministration with high-dose salicylate therapy may increase toxicity; may have additive systemic effects if patient is already on oral carbonic anhydrase inhibitors

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Local ocular adverse effects, primarily conjunctivitis and lid reactions, may occur with long-term administration of dorzolamide (discontinue therapy and evaluate patient before restarting therapy)

Alpha-adrenergic agonists

Decrease IOP, possibly by reducing aqueous humor production.


Apraclonidine (Trusopt)

Reduces elevated and normal IOP whether or not accompanied by glaucoma. Apraclonidine is a relatively selective alpha-adrenergic agonist that does not have significant local anesthetic activity. Has minimal cardiovascular effects.

Adult

1-2 gtt in affected eye(s) tid

Pediatric

Not established

Monitor pulse and BP frequently when giving cardiovascular drugs; not for use concurrently with MAOIs

Documented hypersensitivity; patients on MAOIs or have taken them in the past 14 d

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

May exacerbate or precipitate ocular irritation, topical sensitivity, vasovagal attack, and optic nerve ischemia in patients with advanced glaucomatous optic neuropathy

Hyperosmotic agents

Lower IOP by creating an osmotic gradient between ocular fluids and plasma. They are not for long-term use.


Isosorbide (Ismotic)

May be used to abort an acute attack of glaucoma. In the eyes, may create an osmotic gradient between plasma and ocular fluids and induce diuresis by elevating osmolarity of glomerular filtrate. These effects may inhibit tubular reabsorption of water. Treatment preferred when less risk of nausea and vomiting than that posed by other oral hyperosmotic agents is desired.

Adult

Initial dose: 1.5 g/kg PO
Dose range: 1-3 g/kg PO 2-4 times/d, as indicated

Pediatric

Not established

Documented hypersensitivity; anuria; severe dehydration; frank or impending acute pulmonary edema; severe cardiac decompensation

Pregnancy

B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

Precautions

Use repetitive doses with caution, particularly in patients with diseases associated with salt retention


Mannitol (Osmitrol, Resectisol)

Reduces elevated IOP when the pressure cannot be lowered by other means. Initially assess for adequate renal function in adults by administering a test dose of 200 mg/kg, given IV over 3-5 min. Should produce a urine flow of at least 30-50 mL/h over 2-3 h. In children, assess for adequate renal function by administering a test dose of 200 mg/kg, given IV over 3-5 min. Should produce a urine flow of at least 1 mL/h over 1-3 h.

Adult

1.5-2 g/kg IV as 20% solution (7.5-10 mL/kg) or as 15% solution (10-13 mL/kg) over a period as short as 30 min

Pediatric

Not established

May decrease serum lithium levels

Documented hypersensitivity; anuria; severe pulmonary congestion; progressive renal damage; severe dehydration; active intracranial bleeding; progressive heart failure

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Carefully evaluate cardiovascular status before rapid administration of mannitol since a sudden increase in extracellular fluid may lead to fulminating CHF; avoid pseudoagglutination, when blood given simultaneously, add at least 20 mEq of sodium chloride to each liter of mannitol solution; do not give electrolyte-free mannitol solutions with blood

Prostaglandins

Decrease IOP, possibly by increasing outflow of aqueous humor.


Bimatoprost ophthalmic solution (Lumigan)

Prostaglandin agonist that selectively mimics effects of naturally occurring substances, prostamides. Exact mechanism of action unknown but believed to reduce IOP by increasing outflow of aqueous humor through trabecular meshwork and uveoscleral routes.

Adult

1 gtt of 0.03% solution in affected eye(s) hs; not to exceed 1 dose/d

Pediatric

Not established

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Hyperemia is relatively common; may cause permanent increase in pigment to iris (ie, increases brown pigment) and eyelid; may increase eyelash growth; may cause bacterial keratitis; caution in uveitis or macular edema; do not instill if wearing contact lenses


Travoprost ophthalmic solution (Travatan)

Prostaglandin F2-alpha analog and selective FP prostanoid receptor agonist. Exact mechanism of action unknown but believed to reduce IOP by increasing uveoscleral outflow.

Adult

1 gtt in affected eye(s) hs; not to exceed 1 dose/d

Pediatric

Not established

Documented hypersensitivity; pregnancy; signs of inflammation

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Commonly causes ocular hyperemia; may cause permanent increase in pigment to iris (ie, increases brown pigment) and eyelid; may increase eyelash growth; may cause bacterial keratitis; caution in uveitis or macular edema; do not instill if wearing contact lenses


Unoprostone ophthalmic solution (Rescula)

Prostaglandin F2-alpha analog and selective FP prostanoid receptor agonist. Exact mechanism of action unknown but believed to reduce IOP by increasing uveoscleral outflow.

Adult

1 gtt in affected eye(s) bid

Pediatric

Not established

Documented hypersensitivity; signs of inflammation

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Well tolerated ocularly but may cause permanent increase in pigment to iris (ie, increases brown pigment) and eyelid; may increase eyelash growth; may cause bacterial keratitis; caution in uveitis or macular edema; do not instill if wearing contact lenses


Latanoprost (Xalatan)

May decrease IOP by increasing outflow of aqueous humor.

Adult

1 gtt (1.5 mcg) in affected eye(s) qd in evening; higher frequency administrations may decrease effectiveness

Pediatric

Not established

Coadministration with eye drops containing the preservative thimerosal may reduce effects (administer at intervals of 5 min between applications)

Documented hypersensitivity; signs of inflammation

Pregnancy

B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

Precautions

Do not administer while wearing contact lenses; may increase brown pigment in iris and may change eye color gradually (unknown effect); may reactivate herpetic eye disease

Beta-blockers

Decrease aqueous humor production.


Levobunolol (AKBeta, Betagan)

Nonselective beta-adrenergic blocking agent that lowers IOP by reducing aqueous humor production.

Adult

0.5% solution: 1-2 gtt in affected eye(s) qd
0.25% solution: 1-2 gtt in affected eye(s) bid
Severe or uncontrolled glaucoma: 0.5% solution bid; closely monitor patient; > 1 gtt (0.5% levobunolol) bid not shown to be more effective; if IOP not at satisfactory level on this regimen, concomitant therapy can be instituted; do not administer 2 or more topical ophthalmic beta-adrenergic blocking agents simultaneously

Pediatric

Not established

May cause bradycardia and asystole when used in combination with systemic beta-blockers (may cause additive effects)

Documented hypersensitivity; bronchial asthma; severe chronic obstructive pulmonary disease; sinus bradycardia; second- and third-degree AV block; overt cardiac failure; cardiogenic shock

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Beta-blockade may potentiate muscle weakness that is consistent with certain myasthenic symptoms (eg, diplopia, ptosis, generalized weakness); product may have sulfites, which may cause allergic-type reactions in certain susceptible persons


Timolol (Timoptic, Timoptic XE)

May reduce elevated and normal IOP, with or without glaucoma, by reducing production of aqueous humor or by outflow.

Adult

1 gtt of 0.25% or 0.5% in affected eye(s) bid; if IOP is maintained at satisfactory levels, change dosage to 1 gtt in affected eye(s) qd; if clinical response not adequate, change dosage to 1 gtt of 0.5% solution in affected eye(s) bid; if IOP is still not at satisfactory level, consider concomitant therapy

Pediatric

Administer as in adults

May cause bradycardia and asystole when used in combination with systemic beta-blockers (may cause additive effects)

Documented hypersensitivity; bronchial asthma; sinus bradycardia; second- and third-degree AV block; severe chronic obstructive pulmonary disease; overt cardiac failure; cardiogenic shock

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Product may have sulfites, which may cause allergic-type reactions in susceptible patients; may exacerbate or precipitate heart block, asthma, chronic obstructive pulmonary disease, and mental changes (especially in the elderly)

More on Glaucoma, Phacomorphic

Overview: Glaucoma, Phacomorphic
Differential Diagnoses & Workup: Glaucoma, Phacomorphic
Treatment & Medication: Glaucoma, Phacomorphic
Follow-up: Glaucoma, Phacomorphic
Multimedia: Glaucoma, Phacomorphic
References
[ CLOSE WINDOW ]

References

  1. Dada T, Kumar S, Gadia R, Aggarwal A, Gupta V, Sihota R. Sutureless single-port transconjunctival pars plana limited vitrectomy combined with phacoemulsification for management of phacomorphic glaucoma. J Cataract Refract Surg. Jun 2007;33(6):951-4. [Medline].

  2. Albert DM, Jakobiec FA. Principles and Practice of Ophthalmology. Vol 3. 1994.

  3. Duane TD, Jaeger EA. Clinical Ophthalmology. Vol 3. 1986.

  4. Leung CK, Chan WM, Ko CY, Chui SI, Woo J, Tsang MK, et al. Visualization of anterior chamber angle dynamics using optical coherence tomography. Ophthalmology. Jun 2005;112(6):980-4. [Medline].

  5. McKibbin M, Gupta A, Atkins AD. Cataract extraction and intraocular lens implantation in eyes with phacomorphic or phacolytic glaucoma. J Cataract Refract Surg. Jun 1996;22(5):633-6. [Medline].

  6. Rao SK, Padmanabhan P. Capsulorhexis in white cataracts. J Cataract Refract Surg. Apr 2000;26(4):477-8. [Medline].

  7. Ritch R, Shields MB, Krupin T. The Glaucomas. Vol 2. 1996.

  8. Shields MB. Textbook of Glaucoma. 1998.

  9. Vander JF, Gault JA. Ophthalmology Secrets. 1998.

[ CLOSE WINDOW ]

Further Reading

[ CLOSE WINDOW ]

Keywords

phacomorphic glaucoma, lens intumescence, lens-induced angle-closure glaucoma, cataract, pupillary block glaucoma, senile cataracts

[ CLOSE WINDOW ]

Contributor Information and Disclosures

Author

Harpreet Gill, MD, Staff Physician, Henry Ford Ophthalmology
Harpreet Gill, MD is a member of the following medical societies: Alpha Omega Alpha and American Academy of Ophthalmology
Disclosure: Nothing to disclose.

Coauthor(s)

Mark S Juzych, MD, MHSA, Chief, Department of Ophthalmology, Harper Hospital; Associate Chair and Program Director, Associate Professor, Department of Ophthalmology, Kresge Eye Institute, Wayne State University School of Medicine
Mark S Juzych, MD, MHSA is a member of the following medical societies: Alpha Omega Alpha, American Academy of Ophthalmology, American Medical Association, Association for Research in Vision and Ophthalmology, and Phi Beta Kappa
Disclosure: Nothing to disclose.

Anju Gupta Goyal, MD, Assistant Professor of Ophthalmology, Kresge Eye Institute, Wayne State University; Director of Resident's Clinic, Kresge Eye Institute
Anju Gupta Goyal, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Ophthalmology, American Medical Association, American Society of Cataract and Refractive Surgery, Association for Research in Vision and Ophthalmology, and Michigan State Medical Society
Disclosure: Nothing to disclose.

Medical Editor

Richard W Allinson, MD, Associate Professor, Department of Ophthalmology, Texas A&M University Health Science Center, Scott and White Clinic
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: Nothing to disclose.

Managing Editor

Martin B Wax, MD, Clinical Professor, Department of Ophthalmology, University of Texas Southwestern Medical School; Vice President, Ophthalmology Research and Development, Head, Ophthalmology Discovery Research, Alcon Labs, Inc
Martin B Wax, MD is a member of the following medical societies: American Academy of Ophthalmology, American Glaucoma Society, and Society for Neuroscience
Disclosure: Alcon Labs Salary Employment

CME Editor

Lance L Brown, OD, MD, Ophthalmologist, Affiliated With Freeman Hospital and St John's Hospital, Regional Eye Center, Joplin, Missouri
Disclosure: Nothing to disclose.

Chief Editor

Hampton Roy Sr, MD, Associate Clinical Professor, Department of Ophthalmology, University of Arkansas for Medical Sciences
Hampton Roy Sr, MD is a member of the following medical societies: American Academy of Ophthalmology, American College of Surgeons, and Pan-American Association of Ophthalmology
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.